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Abstract
Introduction: The diagnosis of Parkinson’s disease is mainly clinical. DaT SCAN may help in difficult cases.
Depression is also a clinical diagnosis and is common and persistent symptom in Parkinson’s disease. Dementia is
very often in Parkinson’s disease, but usually not at the first stages. The treatment of each of the above symptoms
is difficult and a lot of times individualized.
Case Presentation: Female 64 years old patient with history of hypothyroidism, depression and anxiety disorder
was examined at outpatient Memory and Dementia clinic of 3
rd Department of Neurology. The patient’s major
problems were functional and cognitive decline, severe extrapyramidal symptoms and depression. According to
UKPDS Brain Bank criteria the patient had bradykinesia, muscular rigidity, postural instability and rest tremor present
with unilateral onset of the symptoms affecting left side most and progressive course. The modified Hoehn and
Yahr scale was 3: mild to moderate bilateral disease; some postural instability; physically independent. The
symptoms remained during nine months follow up, despite the pharmaceutical treatment. Nine months later, the
patient made an attempt to suicide. Firstly, she was transferred to intensive care department with 2
nd degree
burns and respiratory problems, then she was hospitalized at the Burn Unit and afterwards at the Psychiatric clinic.
One month later the patient had no depression, a clear reduction of the extrapyramidal symptoms, functional and
cognitive improvement.
Conclusion: An astonishing improvement occurred after the threat of life. Two years after the attempt to suicide,
the depressive symptoms remain in remission and functional and cognitive status is normal. The extrapyramidal
symptoms have disappeared.
Introduction
The diagnosis of Parkinson’s disease (PD) is, most of the
times, clinical with sensitivity of 88% and specificity 78%
[1,2]. DaT SCAN may help in difficult cases [3,4].
Depression is a common (up to 40%) and persistent
symptom in Parkinson’s disease [5,6]. Depression is
sometimes the first symptom of PD [7]. Other authors
suggest that depression is a risk factor for PD [8]. The
treatment of the depression in PD is difficult because of
the lack of evidence [9]. Dementia also has high preva-
lence in Parkinson’s disease [10]. Drug induced Parkin-
sonism should also be considered as a possible
diagnosis. It is reported to be 20% of the patients with
Parkinsonism [11]. It is well known that depression is
associated with cognitive decline. Pseudodementia is a
term that is usually used, but does not exist as an entity
to any classification system. Furthermore depression has
proved to be a risk factor for dementia and elderly
patients with depression should have an ongoing moni-
toring for their cognitive function [12].
Case Presentation
A 64 years old Caucasian female patient, education: 6
years, with history of hypothyroidism, depression, anxi-
ety disorder and extrapyramidal symptoms was exam-
ined at our Memory and Dementia outpatient center on
26/1/2007.
Personal Past History
Depression with anxiety disorder started in summer of
2004. From 28/7/2004 to 22/11/2004 (4 months) the
patient was taking Citalopram 20 mg per day and
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Citalopram was changed to Mirtazapine 45 mg per day
and Alprazolam was changed to Prazepam 20 mg per
day. On 2/11/2005 Sulpiride 50 mg three times per day
was added. It is the first time that the patient takes anti-
psychotic treatment. Prazepam was stopped. On 4/1/
2006 (after 13 months use) Mirtazapine was changed to
Chlorimipramine Hydrochloride 75 mg per day and
Alprazolam 2 mg per day was added, while on 17/1/
2006 Risperidon 0.5 mg per day was added and Sulpir-
ide was stopped. That treatment stayed almost the same
(Risperidon was raised to 1.5 mg per day for two
months, 19/7/06-21/9/06, but remained to 0.5 mg for
the period 21/9/06 to 26/1/07 when the patient came to
our clinic).
Current history
1
st visit: 26/1/07
The patient’s major problems were functional and cog-
nitive decline, severe extrapyramidal symptoms and
depression. The hypothyroidism was controlled
(Levothyroxin) and for depression and anxiety disorder
the patient was taking Perphenazine/Amitriptyline
hydrochloride 25/2 mg twice/day, Risperidon 0.5 mg/
day, Prazepam 5 mg/day. According to United Kingdom
Parkinson’s Disease Society (UKPDS) Brain Bank criteria
the patient had bradykinesia, muscular rigidity, postural
instability and and rest tremor present with unilateral
onset of the symptoms affecting left side most and pro-
gressive course. None of the exclusion criteria occurred.
The modified Hoehn and Yahr scale was at the stage 3:
mild to moderate bilateral disease; some postural
instability; physically independent. The patient per-
formed the Unified Parkinson’s Disease Rating Scale
(UPDRS) [4]. For the part I Mentation, Behavior and
Mood the score was 7. For the part II Activities of Daily
Living the score was 23. For the part III Motor Exami-
nation the score was 59. For the part IV Complications
of Therapy the score was 1 (presence of early dystonia).
The neuropsychological examination showed: Mini-
Mental State Examination (MMSE): 22/30, Cambridge
Examination for Mental Disorders of the Elderly (CAM-
COG): 49/107, Functional Rating Scale for Symptoms in
Dementia (FRSSD):17, Geriatric Depression Scale
(GDS):12/15, HAMILTON: 19. Escitalopram 10 mg per
day was added.
2
nd visit: 21/2/07
The neuropsychological examination of the patient
showed an improvement in cognitive and functional
symptoms as well as in depression: MMSE: 25, FRSSD:
8, GDS: 10, HAMILTON: 13. Risperidon gradually was
reduced and stopped, Tiapride was added.
3
rd visit: 12/4/07
The neuropsychological examination showed MMSE: 21,
FRSSD: 11, Functional Cognitive Assessment Scale
( F U C A S ) :8 4 ,G D S :1 2 ,H A M I L T O N :2 6 .T i a p r i d ew a s
stopped because there was no difference in depression
and extrapyramidal signs.
4
th visit: 20/4/07
The United Kingdom Parkinson’s disease Society
(UKPDS) Brain Bank criteria and the modified Hoehn
and Yahr scale remained the same, as at visit 1. Carvi-
dopa/Levodopa/entacapone (25/100/200) mg was added.
Escitalopram 10 mg was raised to three times per day
for the resistant depression.
5
th visit: 3/5/07
The patient performed the Unified Parkinson’s Disease
R a t i n gS c a l e( U P D R S )a n dt h es c o r ew a st h es a m ea s
visit 1. The rest neuropsychological examination: Trail
M a k i n gT e s t ,p a r tA :i m p a i r e d ,( f i g u r e1 )p a r tB :
impaired (figure 2). Controlled Oral Word Association
Test (COWAT): 2-3-3. Boston Naming Test (BNT): 17/
30. Clock Drawing Test: impaired, 3/10 (figure 3). CT
was performed on 24/4/07 with no particular findings,
just mild atrophy.
An unexpected incident
On 17/09/07 the patient refused to speak and eat and had
negative behavior. On 21/9/07 the patient made an
attempt to suicide by starting fire. She was transferred to
the local hospital to intensive care department with 2
nd
degree burns and respiratory problems. On 9/10/07 she
was transferred to the Burn Unit and on 15/10/07 to the
Psychiatric Unit of our Hospital. The medication at the
Psychiatric Unit was Quinapril/Hydrochlorothiazide 20
mg/day po, Carvidopa 300 mg/day po, Escitalopram 30
mg/day po, Mirtazapine 45 mg/day po, Quetiapine 200
Figure 1 Trail Making Test on 3
rd May 2007, part A, before the
attempt.
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Page 2 of 5mg/day po, Nadroparin Calcium 0.3 ml/day S.C, Iron pro-
tein succinylate 1 × 2, po, Levothyroxin 100 mg/day po.
6
th visit: 19/10/07, one month later
The patient performed the Unified Parkinson’s Disease
Rating Scale.
For the part I Mentation, Behavior and Mood the
score was 4
For the part II Activities of Daily Living the score was 9
For the part III Motor Examination the score was 23.5
For the part IV Complications of Therapy the score
was 1(presence of early dystonia)
Hence, there was a clear reduction of the extrapyrami-
dal symptoms.
The neuropsychological examination showed an
improvement: Trail Making Test, part A: done at 2 min-
utes and 18 sec, (figure 4) part B: improved (figure 5).
Controlled Oral Word Association Test (COWAT): 6-5-
4. Boston Naming Test (BNT): 21/30. Clock Drawing
Test: 10/10 (figure 6).
The medication at that time was Mirtazapine 45 mg/
day po, Escitalopram 30 mg/day po, Carvidopa/Levo-
dopa/entacapone (25/100/20 0 )m gS :1 * 3 ,L e v o t h y r o x i n
100 mg/day po.
Figure 2 Trail Making Test on 3
rd May 2007, part B, before the
attempt.
Figure 3 Clock Drawing Test on 3rd May 2007, before the
attempt.
Figure 4 Trail Making Test on 19
th October 2007, part A, after
the attempt.
Figure 5 Trail Making Test on 19
th October 2007, part B, after
the attempt.
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sive symptoms.
7
th visit: 2/9/08, one year later
The patient performed the Unified Parkinson’s Disease
Rating Scale:
For the part I Mentation, Behavior and Mood the
score was 1
For the part II Activities of Daily Living the score was 2
For the part III Motor Examination the score was 3
For the part IV Complications of Therapy the score
was 0
T h eM M S Es c o r ew a s2 7 ,t h eF R S S Ds c o r ew a s0a n d
the Hamilton Scale score was 4.
The UKPDS Brain Bank criteria are no longer fulfilled.
The modified Hoehn and Yahr scale was at the stage
0, meaning no signs of disease.
The patient had still no suicidal thoughts, neither
depressive symptoms.
8
th visit: 12/11/08
The patient performed the Unified Parkinson’s Disease
Rating Scale:
For the part I Mentation, Behavior and Mood the
score was 1
For the part II Activities of Daily Living the score was 0
For the part III Motor Examination the score was 5
For the part IV Complications of Therapy the score
was 0
The MMSE score was 27, the FRSSD score was 0, the
NPI score was 0 and the
GDS score was 0.
On 2/1/2009 the MMSE score was 30.
On 16/1/2008, I-123-DaTSCAN [3,4,13] was per-
formed with the following findings (Table 1).
The conclusion of the I-123-DaTSCAN was that
these findings (rates out of the normal range for the
Lenticular Nucleus) could not exclude the start of Par-
kinson’s disease or the start of a mild extrapyramidal
disorder.
On 28/11/2008,a n o t h e rI-123-DaTSCAN was per-
formed with the following findings, which exclude Par-
kinson’s disease and other Parkinsonian Syndromes
(Table 2).
The brain MRI which was performed on 29/1/2009
was almost normal according to her age (mild periven-
tricular leukoencephalopathy).
Conclusion
An astonishing improvement occurred after the threat
of life. The improvement is in functional cognitive and
depressive symptoms. The parkinsonian symptoms also
disappeared. The depressive symptoms remain in remis-
sion after a year and a half of follow up. One explana-
tion is that the patient had Drug - Induced
Figure 6 Clock Drawing Test on 19
th October 2007, after the
attempt.
Table 1 I-123-DaTSCAN on 16/1/2008
Region Right after 3.5 hours Left after 3.5 hours Normal ranges after 3.0 - 4.5 hours
Corpus Striatum 2.15 2.28 2.200 ± 0.30
Nucleus Caudatus - NC 2.93 3.03 2.503 ± 0.30
Lenticular Nucleus - LN 0.98 1.03 2.200 ± 0.50
Ratio LN/NC 0.33 0.34 0.88 ± 0.8
Table 2 I-123-DaTSCAN on 28/11/2008
Region Right after 3.5 hours Left after 3.5 hours Normal ranges after 3.0 - 4.5 hours
Corpus Striatum 3.16 3.62 2.200 ± 0.30
Nucleus Caudatus - NC 3.86 4.32 2.503 ± 0.30
Lenticular Nucleus - LN 2.70 2.97 2.200 ± 0.50
Ratio LN/NC 0.70 0.69 0.88 ± 0.8
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induced dementia (Chlorimipramine Hydrochloride, Per-
phenazine/Amitriptyline hydrochloride-anticholinergic
effect). On the other hand, DIP is dose-related [11] and
Risperidon was given in a very low dose. Risperidon is
also atypical antipsychotic, like Sulpiride which was also
used previously for treating the patient. Another pro-
blem for the diagnosis of DIP is the findings of I-123-
DaTSCAN on 16/1/2008 which support the diagnosis of
Parkinson’s disease. But this diagnosis was not clinically
confirmed at the last visits, neither the 2
nd I-123-DaTS-
CAN on 28/11/08 supported it. As far as the depres-
sion’s remission, it is referred at the literature that
depressed patients may experience significant relief of
their depressive symptoms after the suicide attempt, but
there is a high probability to undergo a relapse within a
short period (3 months) [14]. In this case there is no
relapse so far. (Two years after the suicide attempt). A
close longitudinal follow up of the patient might give us
more answers.
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Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the journal’s Editor-in-Chief.
Acknowledgements
We thank the patient and the patient’s son for their consent to publish this
case report and for their cooperation.
Author details
13rd Department of Neurology, Aristotle University of Thessaloniki, General
Hospital “G Papanikolaou”, Exohi Thessaloniki, 57010, Greece.
2Greek
Association of Alzheimer’s Disease and Related Disorders, 13 Petrou Sindika
str, Thessaloniki, 54643, Greece.
Authors’ contributions
MT, CZM, MS, FF, DD and AK participated in the evaluation and care of the
patient and her caregiver. MT coordinated and directed the work. MT and
MS involved in writing the manuscript. CZM, FF and DD assisted in writing
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 October 2009
Accepted: 2 February 2010 Published: 2 February 2010
References
1. Schrag A, Ben-Shlomo Y, Quinn N: How valid is the clinical diagnosis of
Parkinson’s disease in the community?. J Neurol Neurosurg Psychiatry 2002,
73:529-534.
2. Jankovic J: Parkinson’s disease: clinical features and diagnosis. J Neurol
Neurosurg Psychiatry 2008, 79:368-376.
3. Csoti I, Fornadi F, Klett R, Puille M, Bauer R: Experiences with DaTSCAN™
SPECT in the clinical practice in our Parkinson-Center. Clinical
Neurophysiology 2007, 118(4):e22-e23.
4. Manoharan P, Jamieson S, Bury R: Initial clinical experience with [123I]
ioflupane scintigraphy in movement disorders. Clinical Radiology
62(5):463-471.
5. Prado RC, Barbosa ER: Depression in Parkinson’s disease: study of 60
cases. Arq Neuropsiquiatr 2005, 63(3B):766-71.
6. Frisina GP, Borod CJ, Foldi SN, Tenenbaum RH: Depression in Parkinson’s
disease: Health risks, etiology, and treatment options. Neuropsychiatr Dis
Treat 2008, 4(1):81-91.
7. American Academy of Neurology (April 28): Depression May Be Early Sign
Of Parkinson’s Disease. American Academy of Neurology’s 59th Annual
Meeting, Boston, April 28-May 5, 2007. News release .
8. Schuurman , et al: Increased risk of Parkinson’s disease after depression:
A retrospective cohort study. Neurology 2002, 58:1501-1504.
9. Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE: Therapies for
depression in Parkinson’s disease. Cochrane Database of Systematic
Reviews 2003, , 2: CD003465, DOI: 10.1002/14651858.CD003465.
10. Friedman A, Barcikowska M: Dementia in Parkinson’s Disease. Dementia
1994, 5:12-16.
11. Hirose G: Drug induced parkinsonism: a review. J Neurol 2006, 253(Suppl
3):III/22-III/24.
12. Sáez-Fonseca JA, Lee L, Walker Z: Long-term outcome of depressive
pseudodementia in the elderly. J Affect Disord 2007, 101(1-3):123-9.
13. Castrejón SA, Vincente García AM, Cortés Romera M, Vaamonde Cano J,
Rodado Marina S, Poblete García VM, Ruiz Solís S, del Prado Talavera
Rubio M: 123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in
patients with movement disorders. Braz arch biol technol 2005,
48(Special):115-125.
14. Sakamoto K, Fukunaga T: The impact of attempted suicide on the
symptoms and course of mood disorders. J Clin Psychiatry 2003,
64(10):1210-6.
doi:10.1186/1757-1626-3-47
Cite this article as: Tsolaki et al.: Depression, extrapyramidal symptoms,
dementia and an unexpected outcome: a case report. Cases Journal
2010 3:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tsolaki et al. Cases Journal 2010, 3:47
http://www.casesjournal.com/content/3/1/47
Page 5 of 5